Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

Abstract:

INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, and despite research efforts, the underlying mechanisms of AD and optimal treatment targets have not been fully elucidated. Amyloid and tau are key pathological markers of AD with ongoing trials targeting both. However, there are also many trials at various stages of development that primarily target other markers and processes implicated in the disease, which are now being investigated. Areas covered: This review summarizes current treatment approaches for AD and explores both repositioned and novel therapies that target non amyloid and non tau mechanisms that are in the clinical trials pipeline. This includes treatments for cognitive and neuropsychiatric symptoms and potentially disease modifying therapies. The studies included in this review have been obtained from searches of PubMed and clinical trials databases. Expert commentary: There is a renewed energy in identifying better treatments for behavioural symptoms of AD using both novel drugs and repositioning existing drugs. Lack of success in clinical trials of drugs targeting amyloid and tau have led to a surge in targeting alternative mechanisms. Progress in the development of biomarkers will provide further tools for clinical trials of potential therapeutics for both symptomatic treatment and disease modification in AD.

journal_name

Expert Rev Neurother

authors

Khan A,Corbett A,Ballard C

doi

10.1080/14737175.2017.1326818

subject

Has Abstract

pub_date

2017-07-01 00:00:00

pages

683-695

issue

7

eissn

1473-7175

issn

1744-8360

journal_volume

17

pub_type

杂志文章,评审
  • Cannabis and multiple sclerosis.

    abstract:INTRODUCTION:Patients with multiple sclerosis (MS) may suffer from spasticity and pain during their disease course. Baclofen, dantrolene, diazepam and gabapentin have been used as first-line options to treat these conditions, with modest results. Medical use of marijuana smoking has bypassed traditional clinical trials...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1776610

    authors: Fragoso YD,Carra A,Macias MA

    更新日期:2020-08-01 00:00:00

  • Inflammatory and neuroendocrine biomarkers of prognosis after ischemic stroke.

    abstract::Stroke is the third leading cause of mortality in the USA and one of the leading causes of severe morbidity. It is important to provide stroke patients and physicians with the most accurate prognostic information to optimize care and allocation of healthcare resources. Reliable prognostic markers available during the ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.200

    authors: Katan M,Elkind MS

    更新日期:2011-02-01 00:00:00

  • Broad spectrum micronutrient formulas for the treatment of symptoms of depression, stress, and/or anxiety: a systematic review.

    abstract::Introduction: Vitamin and mineral nutritional supplements are becoming increasingly popular as alternative treatments for anxiety and depression, as issues such as side effects from medication, failure to respond to psychotherapy and workforce limitations pose barriers for successful treatment.Areas covered: This revi...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1740595

    authors: Blampied M,Bell C,Gilbert C,Rucklidge JJ

    更新日期:2020-04-01 00:00:00

  • No evidence of disease activity in multiple sclerosis patients.

    abstract:INTRODUCTION:Multiple Sclerosis is a chronic inflammatory demyelinating disease that affects 2.5 million people in the world. NEDA (No evidence of disease Activity) -4 is a new concept related to absence of disease activity in the context of MS. It takes into account the following four parameters: relapses; disability ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1202763

    authors: Matta AP,Nascimento OJ,Ferreira AC,Magalhães TN,Benevides TP,Kirmse A,Dib JG,Cal H,Orsini M,Araujo LM

    更新日期:2016-11-01 00:00:00

  • Management of von Hippel-Lindau disease-associated CNS lesions.

    abstract::Patients with von Hippel-Lindau disease (VHL) often harbor significant disease burden within the CNS, specifically craniospinal-axis hemangioblastomas and endolymphatic sac tumors (ELSTs). The majority (60-80%) of patients with VHL harbor hemangioblastomas, and 10-15% will develop ELSTs. Advances in the understanding ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.124

    authors: Wind JJ,Lonser RR

    更新日期:2011-10-01 00:00:00

  • Advances in understanding spontaneous intracerebral hemorrhage: insights from neuroimaging.

    abstract::Spontaneous (non-traumatic) symptomatic intracerebral hemorrhage is a devastating form of stroke, with very high overall mortality and morbidity. Even with the best current medical or surgical treatment, outcomes still remain poor. By contrast with ischemic stroke, the incidence of intracerebral hemorrhage is not decr...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.918506

    authors: Wilson D,Charidimou A,Werring DJ

    更新日期:2014-06-01 00:00:00

  • Improving understanding of trigger points and widespread pressure pain sensitivity in tension-type headache patients: clinical implications.

    abstract:INTRODUCTION:The underlying etiology of tension type headache (TTH) is not understood. The current paper highlights the etiologic role of muscle trigger points (TrPs) to the development and maintenance of central sensitization in TTH and its clinical repercussion for proper management of these patients. Areas covered: ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1359088

    authors: Fernández-De-Las-Peñas C,Arendt-Nielsen L

    更新日期:2017-09-01 00:00:00

  • Improving outcomes of subthalamic nucleus deep brain stimulation in Parkinson's disease.

    abstract::The subthalamic nucleus (STN) has been a major target of deep brain stimulation (DBS) for Parkinson's disease (PD) over the past 20 years. The benefits of DBS of the STN include: decreased motor fluctuations and bradykinesia, tremor reduction and a reduction in dopaminergic drug requirements and dyskinesias. Despite t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1081815

    authors: Bari AA,Fasano A,Munhoz RP,Lozano AM

    更新日期:2015-10-01 00:00:00

  • Effects of surgical resection and adjuvant therapy on pediatric intracranial ependymomas.

    abstract::The optimal therapy of pediatric ependymomas is controversial. The benefit of surgical resection is widely accepted, but the role of adjuvant therapy is subject to debate. Due to the relatively low survival rates of ependymoma patients, as well as the tumor's high recurrence rates, further research into the efficacy o...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.4.465

    authors: Krieger MD,Bowen IE

    更新日期:2005-07-01 00:00:00

  • Muscle trigger point therapy in tension-type headache.

    abstract::Recent evidence suggests that active trigger points (TrPs) in neck and shoulder muscles contribute to tension-type headache. Active TrPs within the suboccipital, upper trapezius, sternocleidomastoid, temporalis, superior oblique and lateral rectus muscles have been associated with chronic and episodic tension-type hea...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.138

    authors: Alonso-Blanco C,de-la-Llave-Rincón AI,Fernández-de-las-Peñas C

    更新日期:2012-03-01 00:00:00

  • Repetitive transcranial magnetic stimulation as treatment for anxiety disorders.

    abstract::Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive and generally well-tolerated method of focally stimulating brain regions. It has been shown to be efficacious in the treatment for depression, but only to a limited degree. It has also been investigated for the treatment of some anxiety disorders, pa...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737175.8.10.1449

    authors: Pigot M,Loo C,Sachdev P

    更新日期:2008-10-01 00:00:00

  • Stem cell therapy for Parkinson's disease.

    abstract::The aim of stem cell therapy for Parkinson's disease is to reconstruct nigro-striatal neuronal pathways using endogenous neural stem/precursor cells or grafted dopaminergic neurons. As an alternative, transplantation of stem cell-derived dopaminergic neurons into the striatum has been attempted, with the aim of stimul...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.6.667

    authors: Takahashi J

    更新日期:2007-06-01 00:00:00

  • Botulinum toxin treatment of adult spasticity.

    abstract::Spasticity is a common complication of CNS injury and a cause of considerable discomfort and disability for the patient and difficulty for caregivers. It is estimated that over half a million people in the USA are affected by spasticity. In recent years, advances in the treatment of spasticity include the use of intra...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.3.6.773

    authors: Sheean G

    更新日期:2003-11-01 00:00:00

  • Genome-wide investigation of rare structural variants identifies VIPR2 as a new candidate gene for schizophrenia.

    abstract::Research has shown that structural variation in the human genome, including rare copy number variations (CNVs), contributes to genetic susceptibility to psychiatric diseases, such as schizophrenia, a devastating complex disorder with a high genetic load. The study by Vacic et al. applied a genome-wide approach to dete...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.84

    authors: Nieratschker V,Meyer-Lindenberg A,Witt SH

    更新日期:2011-07-01 00:00:00

  • Fentanyl for breakthrough pain: a systematic review.

    abstract::The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.63

    authors: Davis MP

    更新日期:2011-08-01 00:00:00

  • Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.

    abstract:INTRODUCTION:Chronic inflammatory neuropathies are disorders caused by an immune response to peripheral nerve. They include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and neuropathy associated with anti-MAG IgM monoclonal gammopathy and other less frequent neurop...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1340832

    authors: Nobile-Orazio E,Gallia F,Terenghi F,Bianco M

    更新日期:2017-08-01 00:00:00

  • Highlights in muscle relaxants.

    abstract::The aim of this article is to provide an overview on neuromuscular blocking agents and a rational selection of the most appropriate agents, along with pharmacological and pharmacoeconomic considerations on neuromuscular blockers and their antagonists. Neuromuscular blocking agents are used during anesthesia to facilit...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.12.1833

    authors: Leykin Y,Pellis T,Vincenti E

    更新日期:2006-12-01 00:00:00

  • Paroxetine in panic disorder: clinical management and long-term follow-up.

    abstract::Panic disorder is one of the most common anxiety disorders and has a lifetime prevalence of 3-5%. Panic attacks can begin at any age, but commonly have their onset in early adulthood between the ages of 20 and 40 years. Naturalistic data has shown that panic disorder has a chronic and relapsing course. Panic disorder ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.2.191

    authors: Dannon PN,Lowengrub K,Iancu I,Kotler M

    更新日期:2004-03-01 00:00:00

  • Technology-based assessment of motor and nonmotor phenomena in Parkinson disease.

    abstract:INTRODUCTION:The increasing development and availability of portable and wearable technologies is rapidly expanding the field of technology-based objective measures (TOMs) in neurological disorders, including Parkinson disease (PD). Substantial challenges remain in the recognition of disease phenomena relevant to patie...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2018.1530593

    authors: Merola A,Sturchio A,Hacker S,Serna S,Vizcarra JA,Marsili L,Fasano A,Espay AJ

    更新日期:2018-11-01 00:00:00

  • Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression.

    abstract::According to the corticoid receptor hypothesis of depression, hyperactivity of the hypothalamic-pituitary-adrenocortical (HPA) system is one of the major pathophysiological factors for the development of depression and opens a broad range of new antidepressant treatment options that are related to direct interventions...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/ern.09.52

    authors: Schüle C,Baghai TC,Eser D,Rupprecht R

    更新日期:2009-07-01 00:00:00

  • Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.

    abstract::Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a complication of exposure to dopamine receptor blocking agents. Vesicular monoamine transporter type 2 (VMAT2) inhibitors reduce dyskinesia by decreasing transport of monoamines, including dopamine, into presynaptic vesicles, lea...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1848548

    authors: Dorfman BJ,Jimenez-Shahed J

    更新日期:2021-01-01 00:00:00

  • The impact of receptor-receptor interactions in heteroreceptor complexes on brain plasticity.

    abstract::Allosteric mechanisms in receptor heteromers markedly increase the repertoire of receptor recognition and signaling. Of high importance is the altered function in the receptor heteromer versus the receptor homomer. Such a change in receptor function is mainly brought about by agonist induced allosteric receptor-recept...

    journal_title:Expert review of neurotherapeutics

    pub_type: 社论

    doi:10.1586/14737175.2014.922878

    authors: Fuxe K,Agnati LF,Borroto-Escuela DO

    更新日期:2014-07-01 00:00:00

  • Special biological issues in the management of women with schizophrenia.

    abstract::Schizophrenia is a debilitating and pervasive mental illness with devastating effects on psychological, cognitive and social wellbeing, and for which current treatment options are far from ideal. Gender differences and the influence of the female reproductive life cycle on the onset, course and symptoms of schizophren...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.62

    authors: Kulkarni J,Gavrilidis E,Hayes E,Heaton V,Worsley R

    更新日期:2012-07-01 00:00:00

  • Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.

    abstract::Introduction: Alzheimer's disease (AD), a commonly encountered neurodegenerative disorder, causes cognitive decline and has a devastating effect on the quality of life. AD occurs mainly through abnormal amyloid β peptide (Aβ) and tau protein (tau) activity around/in neurons. Aβ-based therapeutic techniques have been s...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1621750

    authors: Kuo YC,Rajesh R

    更新日期:2019-07-01 00:00:00

  • Post-stroke pain.

    abstract::Pain is one of the most troublesome sequelae of stroke, occurring in 19-74% of patients. A portion of this post-stroke pain is caused by the brain lesion itself; this is called 'central post-stroke pain' (CPSP). Although the prevalence of CPSP among stroke patients is low (1-8%), the persistent, often treatment-refrac...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.19

    authors: Kim JS

    更新日期:2009-05-01 00:00:00

  • Sumatriptan/naproxen sodium combination for the treatment of migraine.

    abstract::Sumatriptan 85 mg with naproxen sodium 500 mg, a combination tablet for the acute treatment of migraine, is approved in the USA. It is likely that triptan/NSAID combination benefits are a class effect, although the majority of data are on sumatriptan and naproxen sodium. The combination tablet demonstrated superior ef...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.9.1289

    authors: Cleves C,Tepper SJ

    更新日期:2008-09-01 00:00:00

  • Managing bipolar disorder during pregnancy and the postpartum period: a critical review of current practice.

    abstract::Introduction: Despite increased interest in the pharmacotherapy of bipolar disorder during pregnancy and the postpartum period, management of the disorder during these critical periods in a woman's life remains challenging.Areas covered: The authors review the effect of pregnancy and the postpartum period on the cours...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1743684

    authors: Sharma V,Sharma P,Sharma S

    更新日期:2020-04-01 00:00:00

  • The search for biomarkers in Parkinson's disease: a critical review.

    abstract::Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily presents with features of bradykinesia, rigidity and tremor, and has, as part of its core pathology, the degeneration of dopaminergic neurons in the substantia nigra pars compacta. There is a great need for the development of a reliabl...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.12.1841

    authors: Antoniades CA,Barker RA

    更新日期:2008-12-01 00:00:00

  • Cladribine for multiple sclerosis: review and current status.

    abstract::In the 1990s, cladribine was developed as an adenosine deaminase-resistant nucleoside analog with selective lymphotoxic specificity in the hope that it might become useful in the treatment of some lymphoid neoplasms and autoimmune disorders. Several clinical trials demonstrated very significant effectiveness and safet...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.721

    authors: Sipe JC

    更新日期:2005-11-01 00:00:00

  • Duloxetine in the acute and continuation treatment of major depressive disorder.

    abstract::Duloxetine is a serotonin-noradrenaline reuptake inhibitor with indications for use in the short term, continuation and maintenance treatment of major depression. Although clinicians currently have access to a range of medications for the treatment of depression, a significant number of patients fail to respond or rem...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/ern.11.133

    authors: Bochsler L,Olver JS,Norman TR

    更新日期:2011-11-01 00:00:00